Real-world Outcomes Mixed for Humira Biosimilars | AMCP Annual 2026
At the Academy of Managed Care Pharmacy (AMCP) annual meeting in Nashville, panelists discussed pharmacy benefit managers’ (PBMs) expansion into Humira (adalimumab) biosimilars, highlighting both significant cost savings and variable patient outcomes. Matt Hustad, PharmD, Senior Manager, Formulary Services at Navitus, shared his perspective, emphasizing a thoughtful approach to adoption of the biosimilar.
Stay Informed and Connected
Receive expert insights, healthcare tips, and important updates on pharmacy benefits, drug recalls, and more—straight to your inbox.
CLARITY FOR ACTION
Gain Clarity: Navitus 10th Annual Drug Trend Report Ready to Download
Our 2025 report provides transparent, data-driven insight to help plans, plan sponsors and consultants navigate an increasingly complex prescription drug landscape.
Related blogs
Navigating Healthcare and Improving Outcomes
PBM 101: Demystifying the Complex World of Specialty Drugs
Unless you work in the pharmacy benefit management (PBM) industry, it’s easy to assume that a “specialty drug” is simply a more expensive prescription. In reality, specialty medications sit in a separate category, with different rules and far bigger consequences…
